4-Week Study of Efficacy, Safety and PK of Albuterol-HFA Versus Proventil-HFA in Pediatric Asthma
A Multi-Center, Randomized, Double-Blind, Active-Controlled, Parallel Group, 4-Week Study to Evaluate the Efficacy, Safety and PK of Albuterol-HFA Versus Proventil-HFA in Pediatric Patients With Asthma in Pediatric Patients With Asthma
Sponsor: Amphastar Pharmaceuticals, Inc.
Terminated
IND voluntarily withdrawn, without prejudice
Other terminated trials from Amphastar Pharmaceuticals, Inc.
- Asthma · Phase PHASE1/PHASE2 · Nov 2012
- Asthma · Phase PHASE1/PHASE2 · Dec 2009
- Asthma · Phase PHASE3 · Oct 2008
- Asthma · Phase PHASE3 · Aug 2008
More terminations from Amphastar Pharmaceuticals, Inc.
Listed as NCT00634517, this PHASE3 trial focuses on Asthma and remains terminated or withdrawn. Sponsored by Amphastar Pharmaceuticals, Inc., it has been updated 7 times since 2008, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE3
-
Apr 2022 — Jul 2024 [monthly]
Terminated PHASE3
-
Jan 2021 — Apr 2022 [monthly]
Terminated PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE3
▶ Show 2 earlier versions
-
Feb 2017 — Jun 2018 [monthly]
Terminated PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Terminated PHASE3
First recorded
Mar 2008
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Amphastar Pharmaceuticals, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .